[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615343":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":30,"centralContacts":31,"locations":30,"responsibleParty":37,"collaborators":30,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":30,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":30,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":30,"overallStatus":61,"whyStopped":30,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":30},{"fullName":5,"class":6},"Minia University","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Control group","this group who undergoing iv contrast will receive hydration only",[12],"Other: Hydration",{"label":14,"type":6,"description":15,"interventionNames":16},"Amlodipine group","this group will receive hydration and amlodipine",[17,12],"Drug: Calcium channel blocker",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Calcium channel blocker","amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour",[14],[25],"amlodipine ( 5mg)",{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Hydration","before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml\u002Fh of normal saline",[14,9],null,[32],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},"Andrew Shehata, Master","CONTACT","0201067820073","andrewlengouini.95@gmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Andrew Samy Shafeek Shehata","Andrew Samy Shafeek","100615343","early-phase-1-role-of-amlodipine-in-reduction-of-cin-100615343",false,"NCT07291375","Role of Amlodipine in Reduction of CIN","The Effect of Low Dose Oral Amlodipine in Renal Protection From Contrast Induced Nephropathy in Diabetic Patients in Intensive Care Unit","Inclusion Criteria:\n\n* adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3\n\nExclusion Criteria:\n\n* patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients",true,"ALL","18 Years","70 Years",{"count":53,"type":54},40,"ESTIMATED","INTERVENTIONAL",[57],"EARLY_PHASE1","The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit",[60],"Contrast-induced Nephropathy","NOT_YET_RECRUITING","2025-12-05",{"date":64,"type":65},"2025-12-18","ACTUAL",{"date":67,"type":54},"2025-12-20",{"date":69,"type":54},"2026-07-01",{"name":5,"class":6}]